ZYN is Swedish Match’s tobacco-free nicotine pouch, owned by Philip Morris International since November 2022, and it is the only nicotine pouch in the world carrying a US modified-risk authorisation. Thirty-one of the forty-three pouch products the FDA has authorised are ZYN or ZYN ULTRA. The European range runs far stronger than the American one, and three flavours on US shelves are not on the FDA’s list at all.
The company behind it
ZYN is a Swedish Match product, and Swedish Match is now part of Philip Morris International. The timeline is in PMI’s own annual report: on 11 November 2022 a PMI subsidiary “acquired a controlling interest of 85.87% of the total issued and outstanding shares in Swedish Match”, reaching 93.11% by the end of that month, initiating compulsory redemption of the remainder on 16 December, and delisting the company from Nasdaq Stockholm on 30 December 2022, “by which time PMHH had become the owner of 94.81% of Swedish Match’s shares.”
Three different legal entities appear on the regulatory paperwork and it is easy to get them wrong. FDA’s authorised-products list names the applicant as Swedish Match USA, Inc. The manufacturer line in the modified-risk order’s Appendix A names both Swedish Match North America LLC and Swedish Match North Europe AB — so American ZYN is not solely a US-made product on FDA’s own record. The UK site’s footer carries the Swedish entity.
Manufacturing has changed this year. PMI’s 2025 annual report describes “our ZYN production facility in Kentucky, U.S., which currently supplies substantially all of our capacity for ZYN sales in the U.S.” — the Owensboro plant, which took a $232 million expansion announced in August 2024 and was expected to provide “around 900 million cans of capacity for 2025”. That sentence is now out of date: PMI opened a second site in July 2026, and says the Aurora, Colorado campus “began commercial production in July 2026 and produces ZYN nicotine pouches”, part of a $1.2 billion programme running 2024–2028.
On volumes, note that PMI has stopped reporting ZYN in cans. Its most recent quarterly filing records “a 1.8% increase in ZYN shipments to 2.9 billion pouches” for the three months to 30 June 2026, against “a 11.2% decline in ZYN shipments to 5.2 billion pouches” across the first half.
The range, and how it differs by market
There are effectively two ZYNs. The American line is deliberately mild; the European line goes more than twice as high.
| Standard ZYN | ZYN ULTRA | |
|---|---|---|
| US strengths authorised | 3 mg, 6 mg | 9 mg; 11 mg (Smooth only) |
| Portion mass | 0.40 g | 0.80 g |
| Pouches per can | 15 | 20 |
| Can net weight | 6 g | 16.0 g |
| Dimensions | 28 × 14 × 4.5 mm | 34 × 14.5 × 6 mm |
| Implied concentration | 7.5 mg/g at 3 mg; 15 mg/g at 6 mg | 11.25 mg/g at 9 mg; 13.75 mg/g at 11 mg |
Those masses come from FDA’s own order documents, and that matters because neither ZYN’s US site nor its UK site publishes a pouch weight or a milligram-per-gram figure anywhere. The UK strengths page frames nicotine purely per pouch: “Each ZYN pouch contains a specific amount of nicotine, measured in milligrams (mg).” The implied concentrations in the table are my arithmetic from FDA’s two numbers, not the company’s figures.
There is also a flat contradiction worth flagging. ZYN’s own US ULTRA product page states “One ZYN pouch weighs approximately 0.4 grams” — which is the standard pouch, not ULTRA. FDA’s marketing order for every one of the eleven ULTRA products gives “Portion mass: 0.8 grams per pouch”. Where the company’s shop and its regulatory filing disagree, I would take the filing.
The US flavour line-up is ten: Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint and Wintergreen, each at 3 mg and 6 mg. The UK sells a different and broader set — Black Cherry, Citrus, Coffee, Spearmint, Apple Mint, Red Fruits, Cool Mint, Icy Mint, Guava Spice, Menthol Ice and Blackcurrant Frost — across strength tiers the site labels Low (1.5 mg and 3 mg), Medium (6 mg and 9 mg) and Strong, where it invites “Experienced nicotine pouch user? Shop our 11mg, 13.5mg & 16.5mg ranges.” Sixteen and a half milligrams per pouch is half as strong again as anything FDA has authorised. The UK site also now sells ZYN Melts, a dissolvable nicotine tablet rather than a pouch.
Three American flavours with no FDA order
This is the most interesting thing in ZYN’s current position and it is sourced on both sides. The FDA’s list is unambiguous: “There are 43 nicotine pouch products authorized by the FDA” from exactly two companies — Helix Innovations LLC with twelve on! products, and Swedish Match USA, Inc. with thirty-one ZYN and ZYN ULTRA products — and “These are the only nicotine pouch products that may be lawfully sold in the United States.”
ZYN’s own US FAQ, meanwhile, announces that “Black Cherry, Peach, and Dragonberry are now permanent additions to the classic lineup.” None of those three appears anywhere on FDA’s list. I searched the list page and the downloadable flyer for each.
PMI addresses this in a sworn filing. Its Q2 2026 quarterly report notes that on 8 May 2026 “the FDA issued final guidance stating that it does not intend to prioritize enforcement against certain unauthorized ENDS and nicotine pouch products that have demonstrated meaningful progress toward authorization”, and continues: “We have commercialized and may decide to commercialize products for which we have not received a marketing granted order where we believe that FDA enforcement would be inconsistent with its public guidance, present practices or the Family Smoking Prevention and Tobacco Control Act.” That is enforcement discretion, not authorisation, and the distinction is the company’s own.
The modified-risk order, exactly
On 30 June 2026 the FDA issued modified-risk orders for twenty ZYN products. This is a different and later action from the marketing authorisation of 16 January 2025, which permitted sale but, in FDA’s words at the time, did not allow reduced-risk claims. Conflating the two is the commonest error written about this brand.
The authorised claim is a closed list of six named conditions, and the order letter gives it in full:
“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
Mouth cancer — not oral cancer generally. Emphysema and chronic bronchitis named separately, not COPD. Nothing about gum disease, nothing about addiction, nothing about safety. The orders “are effective for 5 years from the issue date of this letter”, so to 30 June 2031.
The complete-substitution condition does not sit in the claim itself; it sits in the postmarket surveillance appendix, which requires Swedish Match to assess whether users understand “that adults who currently smoke CC must use the MRTPs exclusively and stop smoking CC to reduce their health risks.” FDA is explicitly monitoring dual use, youth uptake and whether people switch completely, and it took the unusual step of telling the company in the order that “Your current marketing for these ZYN products uses several tactics known to be appealing to youth and young adults, such as sponsorship of popular sporting events and concerts and brand loyalty and rewards programs”.
Two further limits. An MRTP order is not approval, and FDA says so; and any claim that these products treat tobacco dependence “would render the products to not be modified risk tobacco products under section 911”. ZYN may not be marketed as a quitting aid.
Finally, the order covers the twenty standard products only. ZYN ULTRA received its marketing authorisation on 20 August 2026 and has no modified-risk order, so no reduced-risk claim may be made for it.
Where ZYN is legal, and where it cannot be
The Netherlands is the cleanest prohibition, because the statute names the product category rather than implying it. Article 3a of the Tabaks- en rookwarenwet reads: “Het is verboden tabak voor oraal gebruik of nicotineproducten zonder tabak voor oraal gebruik in de handel te brengen” — it is prohibited to place on the market tobacco for oral use or tobacco-free nicotine products for oral use. Article 1 defines the banned category to include products “in particular those offered in portion sachets or porous pouches”. Belgium, Germany, Norway and Australia also keep pouches off the legal market, each by a different route.
Where pouches are legal, two caps exclude the ZYN range outright:
- Latvia permits tobacco-substitute products only where “maksimālā nikotīna koncentrācija tabakas aizstājējproduktā nepārsniedz četrus miligramus uz gramu” — a maximum concentration of four milligrams per gram. Running FDA’s own numbers, ZYN’s weakest US product, 3 mg in a 0.40 g pouch, is 7.5 mg/g: nearly double the Latvian ceiling. No ZYN product in the US or UK range complies. The same provision bars ingredients that give the impression a product is good for health or reduces health risk, which would independently sit badly with the FDA-authorised claim.
- Canada exempts from prescription control only a nicotine product “in the form of a buccal pouch containing 4 milligrams or less of nicotine per dosage unit”. A 3 mg ZYN clears that; 6 mg, 9 mg and 11 mg would all be prescription drugs, and there is no authorised prescription nicotine pouch.
Inside the United States, state flavour bans reach tobacco-free nicotine because of how they define their terms. Massachusetts defines a tobacco product as “a product containing or made or derived from tobacco or nicotine” consumed by any means including “absorbed, dissolved”, and its list of characterizing flavours expressly includes “menthol, mint, wintergreen”. On FDA’s own classification every authorised ZYN product is flavoured. California’s definition likewise reaches nicotine “regardless of whether the chemical is naturally or synthetically derived”, per the state health department’s own guidance — I could not open the California statute directly, so treat that as confirmed by the regulator rather than read from the code.
Counterfeits and grey-market cans
The honest version of this section is that the documented problem is diversion more than forgery. PMI’s quarterly filing says that “the commercial success of the nicotine pouch category makes it more prone to be affected by illicit trade”, and that its affiliates “are taking appropriate actions to address the illicit resale of certain of our oral products, including nicotine pouches outside their initial intended market of retail, such as Scandinavia, the U.S. and other markets. Such actions include awareness communications to trade partners, cease-and-desist letters to those involved in illicit trade of products bearing our brands and limiting and/or terminating sales to certain customers”. Genuine cans sold outside the market they were made for, in other words.
On spotting a fake, be careful which advice you follow, because the company’s own guidance is not consistent between markets. Its Lebanon site tells buyers to check that a “QR code and batch number foil seal” is intact and warns about “Missing or non-functional codes”. Its UK site, published under a different Swedish Match entity, mentions no code of any kind — its checklist is spelling errors and mismatched fonts, a barcode that may be “distorted/pasted on”, poor packaging quality, the statutory warning “This product is not risk free and contains nicotine, which is addictive.”, a best-before date, and a price that is “too cheap to be real”, with the advice to “only purchase ZYN products and other nicotine pouches from authorised retailers.”
I found no counterfeit-ZYN court case, customs seizure notice or trading-standards action in any primary source, and no company-published authentication specification for the US or UK cans. If someone offers you a universal “scan the QR code” test for ZYN, it is not documented for your market.
Verdict
ZYN is the most thoroughly documented nicotine pouch on the market, and that is its real distinction. You can read the portion mass, the dimensions and the nicotine basis of every American product out of a federal order; you cannot do that for most of its competitors, several of which publish no figures at all. The modified-risk order is a genuine regulatory first, and it is also narrower than almost everything written about it: six named diseases, measured against cigarettes, conditional on stopping smoking entirely, for five years.
The qualifications are real too. The strength you get depends entirely on which country you buy in, from a 1.5 mg UK mini to a 16.5 mg UK strong — a nine-fold range under one wordmark. Three US flavours are on sale without an order, by the company’s own account. And nothing in the FDA’s authorisation says the product is safe; the agency’s own standing caveat is that authorisation “does not mean these products are safe, nor are they ‘FDA approved.'” On the evidence, ZYN is the brand with the least guesswork attached — which is not the same as the brand with the least risk attached.
Related reading
- Brand directory: every nicotine pouch and snus brand
- ZYN Cool Mint 3mg review
- ZYN Wintergreen 6mg review
- VELO Freezing Peppermint review
- on! PLUS Mint 6mg review
- mg per pouch vs mg per gram: the only strength guide you need
- The best nicotine pouches: the master ranking
Sources
- US Food and Drug Administration, Nicotine pouch products authorized by the FDA, content current as of 21 August 2026 — 43 products, two companies, the exclusivity statement and the “not safe, nor are they ‘FDA approved'” caveat.
- FDA, modified risk granted orders, STNs MR0000268.PD1–PD20, 30 June 2026 — the authorised claim, the five-year term, Appendix A product specifications including portion mass, Appendix C postmarket surveillance requirements, and the bar on cessation claims.
- FDA, FDA authorizes 20 ZYN nicotine pouches to be marketed with a specific modified risk claim, 30 June 2026.
- FDA, ZYN ULTRA marketing granted order, signed 20 August 2026 — the 0.8 g portion mass and the full ULTRA specifications; and FDA authorizes 11 new nicotine pouches.
- Philip Morris International, Form 10-K for 2022 and Form 10-Q for the quarter ended 30 June 2026 — the Swedish Match acquisition, shipment volumes, the unauthorised-products disclosure and the illicit-trade passages. Company filings, cited as commercial sources.
- Philip Morris International press releases: Owensboro expansion, 27 August 2024, and the Aurora campus opening, 27 July 2026.
- Netherlands, Tabaks- en rookwarenwet, artikelen 1 and 3a (text in force from 1 July 2026). Latvia, Tabakas izstrādājumu, tabakas aizstājējproduktu… aprites likums, 3. pants (5¹). Canada, Prescription Drug List amendment, 14 January 2026. Massachusetts, M.G.L. c. 270 § 28.
- Company sites, read on 12 October 2026: ZYN US FAQ, ZYN UK flavours, ZYN UK strengths, ZYN UK on fake pouches and ZYN Lebanon on spotting fakes.
Last verified: 12 October 2026.